189 related articles for article (PubMed ID: 32937189)
1. Altered redox regulation and S-glutathionylation of BiP contribute to bortezomib resistance in multiple myeloma.
Zhang J; Ye ZW; Chen W; Culpepper J; Jiang H; Ball LE; Mehrotra S; Blumental-Perry A; Tew KD; Townsend DM
Free Radic Biol Med; 2020 Nov; 160():755-767. PubMed ID: 32937189
[TBL] [Abstract][Full Text] [Related]
2. Glutathione S-Transferase P-Mediated Protein S-Glutathionylation of Resident Endoplasmic Reticulum Proteins Influences Sensitivity to Drug-Induced Unfolded Protein Response.
Ye ZW; Zhang J; Ancrum T; Manevich Y; Townsend DM; Tew KD
Antioxid Redox Signal; 2017 Feb; 26(6):247-261. PubMed ID: 26838680
[TBL] [Abstract][Full Text] [Related]
3.
Zhang J; Ye ZW; Chen W; Manevich Y; Mehrotra S; Ball L; Janssen-Heininger Y; Tew KD; Townsend DM
J Biol Chem; 2018 Mar; 293(12):4366-4380. PubMed ID: 29374060
[TBL] [Abstract][Full Text] [Related]
4. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.
Salem K; McCormick ML; Wendlandt E; Zhan F; Goel A
Redox Biol; 2015; 4():23-33. PubMed ID: 25485927
[TBL] [Abstract][Full Text] [Related]
5. Formation and Reversibility of BiP Protein Cysteine Oxidation Facilitate Cell Survival during and post Oxidative Stress.
Wang J; Sevier CS
J Biol Chem; 2016 Apr; 291(14):7541-57. PubMed ID: 26865632
[TBL] [Abstract][Full Text] [Related]
6. SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism.
Hoang B; Shi Y; Frost PJ; Mysore V; Bardeleben C; Lichtenstein A
Mol Cancer Res; 2016 Apr; 14(4):397-407. PubMed ID: 26869290
[TBL] [Abstract][Full Text] [Related]
7. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
Lipchick BC; Utley A; Han Z; Moparthy S; Yun DH; Bianchi-Smiraglia A; Wolff DW; Fink E; Liu L; Furdui CM; Lee J; Lee KP; Nikiforov MA
Blood Adv; 2021 Apr; 5(7):1933-1946. PubMed ID: 33821992
[TBL] [Abstract][Full Text] [Related]
8. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
[TBL] [Abstract][Full Text] [Related]
9. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
10. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.
Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B
Cells; 2020 Oct; 9(11):. PubMed ID: 33114738
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
Tibullo D; Giallongo C; Romano A; Vicario N; Barbato A; Puglisi F; Parenti R; Amorini AM; Wissam Saab M; Tavazzi B; Mangione R; Brundo MV; Lazzarino G; Palumbo GA; Volti GL; Raimondo FD; Lazzarino G
Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365811
[TBL] [Abstract][Full Text] [Related]
12. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
Wu X; Xia J; Zhang J; Zhu Y; Wu Y; Guo J; Chen S; Lei Q; Meng B; Kuang C; Feng X; He Y; Shen Y; Li X; Qiu L; Li G; Zhou W
Br J Haematol; 2020 Jul; 190(1):52-66. PubMed ID: 32037523
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
14. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-transferase pi modulates NF-κB activation and pro-inflammatory responses in lung epithelial cells.
Jones JT; Qian X; van der Velden JL; Chia SB; McMillan DH; Flemer S; Hoffman SM; Lahue KG; Schneider RW; Nolin JD; Anathy V; van der Vliet A; Townsend DM; Tew KD; Janssen-Heininger YM
Redox Biol; 2016 Aug; 8():375-82. PubMed ID: 27058114
[TBL] [Abstract][Full Text] [Related]
16. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
17. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
[TBL] [Abstract][Full Text] [Related]
18. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
Tibullo D; Barbagallo I; Giallongo C; Vanella L; Conticello C; Romano A; Saccone S; Godos J; Di Raimondo F; Li Volti G
Oncotarget; 2016 May; 7(20):28868-80. PubMed ID: 26930712
[TBL] [Abstract][Full Text] [Related]
19. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Yin L; Kufe T; Avigan D; Kufe D
Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
[TBL] [Abstract][Full Text] [Related]
20. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]